SCHEMBL6489877

SCHEMBL6489877

Clc1ccc2[nH]c3c(c2c1)/C(=N/NC1=NCCN1)CCC3

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K14 Q99558 3/20 0.43
HTR6 P50406 2/20 0.41
KDM4E B2RXH2 4/20 0.40
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPK1 P28482 1/20 0.39
CDK5 Q00535 2/20 0.38
CDK5R1 Q15078 2/20 0.38
HTR1A P08908 2/20 0.36
HTR2A P28223 1/20 0.36
HTR7 P34969 1/20 0.36
WDR5 P61964 1/20 0.36
GAA P10253 2/20 0.35
ALDH1A1 P00352 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
EIF2AK2 P19525 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489881 1.00 MAP3K14 (0.43) MAP3K14HTR6KDM4EMAPTMEN1
SCHEMBL6488248 0.87 CDK5 (0.43) HTR6NPC1RAB9ACDK5CDK5R1
SCHEMBL6488243 0.87 CDK5 (0.43) HTR6NPC1RAB9ACDK5CDK5R1
SCHEMBL6489663 0.82 MAP3K14 (0.41) MAP3K14HTR6KDM4EMAPTMEN1
SCHEMBL6489651 0.78 MAP3K14 (0.42) MAP3K14HTR6KDM4EMAPTMEN1
SCHEMBL6489655 0.78 MAP3K14 (0.42) MAP3K14HTR6KDM4EMAPTMEN1
SCHEMBL6488762 0.76 ADRA2C (0.40) MAP3K14HTR6KDM4EMAPTMEN1
SCHEMBL2305408 0.74 KDM4E (0.50) MAP3K14HTR6KDM4EMAPTMEN1
SCHEMBL2305405 0.74 KDM4E (0.50) MAP3K14HTR6KDM4EMAPTMEN1
SCHEMBL6488194 0.73 MAP3K14 (0.46) MAP3K14HTR6KDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951881-B2 (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-10-04 US claimed
US-20030232843-A1 (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2003-12-18 US claimed
US-6951881-B2 (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-10-04 US disclosed
US-20030232843-A1 (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232843-A1 (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR1A MAP3K14 3172/4885HTR6 1/4885KDM4E 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.